The field of drug discovery is witnessing a revolutionary shift with the advent of Proteolysis Targeting Chimeras (Protein Degraders). This innovative therapeutic strategy is redefining how we approach the degradation of proteins,Read More…
Proteolysis targeting chimera (Protein Degrader) technology represents a breakthrough development in the field of drug discovery, utilizing the ubiquitin proteasome system to specifically degrade disease-related proteins. Protein Degraders are characterized by theirRead More…
Targeted protein degradation (TPD) has emerged over the past decade as a major novel drug modality for the removal of intracellular proteins with bispecific small molecules that recruit proteins of interest (POIs)Read More…
Targeted protein degradation (TPD) primarily degrades target proteins through the ubiquitin-proteasome and lysosome, and according to the specific mechanism of action, it can be further subdivided into nearly 10 different technical routes,Read More…
Introduction Various types of delivery systems, including organic/inorganic nanoparticles, small molecule targeting moieties, and antibodies, have been explored as carriers for Protein Degraders. These systems play a crucial role in addressing theRead More…
Preclinical evidence of Protein Degrader The breakthrough in Protein Degrader’s design paves the way for its early clinical trials. According to statistics, as of January 8, 2023, 18 kinds of Protein DegraderRead More…
Protein Degrader uses the natural mechanism of protein degradation in cells, that is, the ubiquitin-protease system, to induce targeted protein degradation. Compared with traditional small molecular inhibitors used in cancer therapy, ProteinRead More…
Enzyme-Catalyzed Responsive Pro-Protein Degrader The researchers concentrated on the distinction between the tumor microenvironment and the normal cell environment and incorporated the endogenous enzyme response chemistry of tumor cell characteristics into theRead More…
Chemical protein degradation methods like protein degradation targeted chimera (Protein Degrader) allow for the simultaneous targeting of E3 ligase and disease-related proteins, with the latter then being degraded by the body’s ownRead More…
In the past 20 years, Protein Degrader has ushered in a period of rapid development, especially since the successful degradation of BET protein by dBET1 Protein Degrader with pomalidomide as the ligandRead More…